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ABSTRACT
Objectives To measure relative preferences for outcomes 
of integrated care of patients with multimorbidity from 
eight European countries and compare them to the 
preferences of other stakeholders within these countries.
Design A discrete choice experiment (DCE) was 
conducted in each country, asking respondents to choose 
between two integrated care programmes for persons with 
multimorbidity.
Setting Preference data collected in Austria (AT), Croatia 
(HR), Germany (DE), Hungary (HU), the Netherlands (NL), 
Norway (NO), Spain (ES), and UK.
Participants Patients with multimorbidity, partners and 
other informal caregivers, professionals, payers and 
policymakers.
Main outcome measures Preferences of participants 
regarding outcomes of integrated care described 
as health/well- being, experience with care and cost 
outcomes, that is, physical functioning, psychological well- 
being, social relationships and participation, enjoyment of 
life, resilience, person- centredness, continuity of care and 
total costs. Each outcome had three levels of performance.
Results 5122 respondents completed the DCE. In 
all countries, patients with multimorbidity, as well as 
most other stakeholder groups, assigned the (second) 
highest preference to enjoyment of life. The patients 
top- three most frequently included physical functioning, 
psychological well- being and continuity of care. Continuity 
of care also entered the top- three of professionals, 
payers and policymakers in four countries (AT, DE, HR 
and HU). Of the five stakeholder groups, preferences of 
professionals differed most often from preferences of 
patients. Professionals assigned lower weights to physical 
functioning in AT, DE, ES, NL and NO and higher weights 
to person- centredness in AT, DE, ES and HU. Payers and 
policymakers assigned higher weights than patients to 
costs, but these weights were relatively low.
Conclusion The well- being outcome enjoyment of life 
is the most important outcome of integrated care in 
multimorbidity. This calls for a greater involvement of 
social and mental care providers. The difference in opinion 
between patients and professionals calls for shared 
decision- making, whereby efforts to improve well- being 
and person- centredness should not divert attention from 
improving physical functioning.
INTRODUCTION
Persons with multimorbidity may have 
complex care needs requiring the involve-
ment of different types of professionals from 
different sectors of the healthcare, social 
care and/or community care systems. If the 
services provided by different professionals 
are not well aligned, they may experience 
conflicting treatment goals, harmful effects 
of interacting treatments, overly- demanding 
Strengths and limitations of this study
 ► We designed an online discrete choice experiment 
(DCE) to measure the relative importance of health, 
well- being, experience and cost outcomes of in-
tegrated care to patients with multimorbidity from 
eight European countries.
 ► The choice of outcomes was largely driven by focus 
groups involving patients with multimorbidity.
 ► We compared patients’ preferences with the prefer-
ences of other stakeholders including informal care-
givers, professionals, payers and policymakers in a 
large sample of 5122 respondents.
 ► Online discrete choice experiments are cognitively 
challenging and respondents may not represent all 
patients with multimorbidity.
 ► When completing the DCE, it might be challenging 
for the other stakeholders to separate their profes-
sional role from the other roles they might have.
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appeals on self- management capabilities and inefficien-
cies like overtreatment and undertreatment.
It is hypothesised, that persons with multimorbidity 
would benefit from person- centred integrated care 
programmes.1–3 Integrated care programmes commonly 
adopt a holistic approach towards people with multimor-
bidity, which means that, instead of the disease, the person 
with his or her needs, capabilities, preferences, resources 
and (social) environment is put in the centre.4 In the 
European Union (EU)- funded Horizon2020 project 
SELFIE (Sustainable intEgrated chronic care modeLs for 
multimorbidity: delivery, FInancing, and performancE), 
we study 17 promising integrated care programmes from 
eight European countries, that is, Austria (AT), Croatia 
(HR), Germany (DE), Hungary (HU), the Netherlands 
(NL), Norway (NO), Spain (ES) and UK. In many of 
these programmes an interdisciplinary individual care 
plan, with well- aligned health and social care services, 
is designed to specifically target the goals and priorities 
jointly set by the person with multimorbidity and his or 
her formal and informal caregivers. Many programmes 
also offer tailored self- management support and assign 
a case manager to the most complex patients, to ensure 
that they have a single contact point that helps them navi-
gate through the system.
Integrated care programmes for persons with multi-
morbidity often aim to improve outcomes that go beyond 
health and include their broader sense of well- being, 
experience with care and costs. This is often referred to 
as the Triple Aim of improving population health/well- 
being, experience and costs.5 Therefore, we decided to 
measure a broad set of outcome measures in the evalua-
tion studies of the 17 programmes in the SELFIE project. 
However, the importance of these outcomes is almost 
never measured. In the SELFIE project we were specifi-
cally interested in the importance of these outcomes to 
persons with multimorbidity. Understanding their pref-
erences is vital for the optimal design of person- centred 
integrated care services and inform decision- making on 
implementation and upscaling of these services. In the 
SELFIE project, we aim to use the preferences as weights 
in Multi- Criteria Decision Analyses (MCDA) of the 17 
programmes.6 In an MCDA, a wide range of different 
outcomes is aggregated into a single, overall value score. 
This overall value score combines the performance of 
the integrated care programmes on different outcomes, 
each weighted according to its respective preference 
weight.7 8 Besides the persons with multimorbidity, there 
are many other stakeholders involved in decision- making 
about integrated care and their preferences may differ 
from patients’ preferences. Therefore, we aim to repeat 
the MCDA’s in the SELFIE project, using the preference 
weights from different groups of stakeholders.
The aim of the current paper is twofold. First, to present 
the relative magnitude of the preferences for the Triple 
Aim outcomes in persons with multimorbidity from eight 
European countries. Second, the aim is to compare the 
Patients’ preferences to the preferences of Partners and 
other informal caregivers, Professionals, Payers and Poli-
cymakers, together referred to as the 5 P’s. This will be a 
within- country comparison, because the decision context 
of the future MCDA’s relates to local or regional level 
decisions about the adaptation, reimbursement, contin-
uation and scaling- up of the 17 existing integrated care 
programmes.
METHODS
Discrete choice experiment
The preferences were obtained using discrete choice 
experiments (DCEs). A DCE is a theoretically well 
founded method to determine how much respondents 
are willing to trade- off some outcomes against others.9–11 
In our DCE, respondents from the 5P’s were given ques-
tions that asked them to choose between two integrated 
care programmes for persons with multimorbidity, 
labelled programme A and programme B. There was 
no opt- out. Each programme was described in terms of 
outcomes with systematically varying levels that describe 
the performance of the programme on the outcomes. 
The outcomes were largely based on focus groups and 
included measures of health and well- being: (1) phys-
ical functioning, (2) psychological well- being, (3) social 
relationships and participation, (4) enjoyment of life, 
(5) resilience; measures of experience: (6) person- 
centredness, (7) continuity of care; and (8) total health-
care and social care costs. The definitions are given in 
table 1. An example of a DCE question is given in figure 1.
Each outcome (attributes in DCE terminology) had 
three levels indicating a poor, average and good perfor-
mance of the programme on that outcome. The defini-
tions of the outcomes and levels were identical across the 
eight countries, except for costs. The three levels of costs 
were based on country- specific estimates of the mean total 
health and social care costs for people with multimor-
bidity in 2017 (middle level) and increased and decreased 
by 20% to obtain the poor and good performance level. 
This percentage was chosen to ensure enough variation 
in levels while at the same time remaining within realistic 
boundaries. The costs were expressed in the national 
currency.
DCE design
A Bayesian efficient heterogeneous design algorithm was 
used to optimise the DCE designs based on the D- effi-
ciency criterion.12 Ten different subdesigns with 18 choice 
tasks per subdesign were used. In each subdesign either 
four or five attribute levels were overlapped between 
programme A and B, to reduce the overall complexity of 
the choice tasks and improve response efficiency.13 One 
restriction was built into the design, namely, the best 
level of the psychological well- being attribute and the 
worst level of enjoyment of life, and vice versa, were not 
presented simultaneously for the same programme.
The initial DCE designs were optimised using priors 
that were based on the available literature (see online 
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supplemental box S1). These DCE designs were subse-
quently updated, based on updated priors that reflected 
the information obtained from approximately the first 
50 respondents in each stakeholder group. The design 
updates were performed separately for each country/
stakeholder group and the updated priors were the 
average of the literature- based priors and the conditional 
logit estimates of the first 50 respondents.
Questionnaire design
The online DCE survey started with an explanation of 
the SELFIE project, the outcomes, type of questions 
and the perspective from which the questions should 
be answered (ie, one of the five P’s). Each respondent 
completed a randomly chosen subdesign with 18 choice 
tasks, preceded by two practice- questions. The order of 
appearance of the choice tasks within each subdesign was 
randomised. The 18 choice tasks were presented in three 
sections of six choice tasks each, with several background 
questions in between. The background questions related 
to sociodemographic characteristics and the respon-
dents’ health conditions. Colour coding was used for the 
different levels of the outcomes as shown in figure 1, and 
outcomes that had the same level in the two integrated 
care programmes were presented in grey.13 When respon-
dents hovered the mouse over an outcome, the definition 
of that outcome became visible. At the end of the survey, 
respondents received a multiple- choice question on the 
level of difficulty of the questionnaire.
Table 1 Definitions of the outcomes and levels
Outcome (attribute) Definition Levels
Physical functioning Acceptable physical functioning and being able 
to do daily activities without needing assistance 
(eg, getting dressed, sitting down and getting 
up from a chair, taking your medications)
1. Severely limited in physical functioning and 
activities of daily living
2. Moderately limited in physical functioning and 
activities of daily living
3. Hardly or not at all limited in physical functioning 
and activities of daily living
Psychological well- being The absence of stress, worrying, listlessness, 
anxiety and feeling down
1. Always or mostly stressed, worried, listless, 
anxious and down
2. Regularly stressed, worried, listless, anxious and 
down
3. Seldom or never stressed, worried, listless, 
anxious and down
Social relationships and 
participation
Having meaningful connections with others as 
desired
1. No or barely any meaningful connections with 
others
2. Some meaningful connections with others
3. A lot of meaningful connections with others
Enjoyment of life Having pleasure and happiness in life 1. No or barely any pleasure and happiness in life
2. Some pleasure and happiness in life
3. A lot of pleasure and happiness in life
Resilience The ability to recover from or adjust to 
difficulties and to restore one’s balance
1. Poor ability to recover, adjust and restore 
balance
2. Fair ability to recover, adjust and restore balance
3. Good ability to recover, adjust and restore 
balance
Person- centredness Care that matches an individual’s needs, 
capabilities and preferences and where 
decisions are made jointly based on good 
information
1. Not or barely person- centred
2. Somewhat person- centred
3. Highly person- centred
Continuity of care Good collaboration, smooth transitions 
between caregivers and no waste of time
1. Poor collaboration, transitions and timeliness
2. Fair collaboration, transitions and timeliness
3. Good collaboration, transitions and timeliness
Total healthcare and 
social care costs
Total healthcare and social care costs per 
participant in the programme, per year. Note: 
These are costs paid for by the health insurer/
government.
1. 8500 € per participant per year*
2. 7000 € per participant per year
3. 5500 € per participant per year
*These are the Dutch values. The value for the other countries are: Austria: 8000, 6600, 5200 €; Croatia: 7200, 6000, 4800 kuna (973, 810, 648 
€); Hungary: 600 000, 500 000, 400 000 forint (1951, 1626, 1300 €); Germany: 4800, 4000, 3200 €; Norway: 115 000, 95 000, 75 000 krone (12 
330, 10 185, 8041 €); Spain: 5400, 4500, 3600 euro; UK: 3600, 3000, 2400 pounds (4130, 3441, 2753 €).
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The questionnaire was designed in English and trans-
lated into each country’s respective language, using the 
same translation protocol, which included forward and 
backward translations by native- language speakers with 
an excellent level of English.
Respondents
Respondents from the stakeholder groups were recruited 
in the eight countries participating in the SELFIE project 
during 2017 to 2018. Sample size calculations14 led to a 
target number of 150 respondents per country per stake-
holder group. Each country recruited respondents from 
three to five different groups of stakeholders. All coun-
tries recruited respondents from the first three P’s (ie, 
patients with multimorbidity, partners and other informal 
caregivers, professionals). The Netherlands and Norway 
recruited respondents from all five P’s. The other coun-
tries combined the respondents from the payers and 
policymakers into one group, either because they have 
a Beveridge- like healthcare model in which there is a 
national/regional health service with a single payer (HR, 
HU, UK and ES) or because they were in the midst of 
a comprehensive health insurance reform (AT) or an 
election (DE), making it difficult to recruit a sufficient 
number of respondents from the two groups separately.
Patients with multimorbidity and partners and other informal 
caregivers were recruited from internet panels managed by 
market research organisations, except in Spain where they 
were personally invited to participate by the members of 
the Spanish team of the SELFIE project who were physi-
cians and nurses. In Spain, patients were recruited in 
the waiting rooms of a hospital, geriatric residences and 
support groups for families with Alzheimer. All patients 
had two or more chronic conditions. Partners and other 
informal caregivers had to provide voluntary care or 
support to a family member, friend or other acquain-
tance who needed help due to physical, mental or ageing- 
related health problems, for at least 2 weeks.
Professionals were also recruited through an Internet 
panel organisation in the UK and the Netherlands. In 
the other countries, they were recruited through the 
networks of the authors and a snowball sampling method, 
in which we asked respondents if they could invite other 
responders within their organisations. Examples of organ-
isations approached include care provider organisations 
or professional associations like nursing associations.
All payers and policymakers in the UK and about one- 
third of the payers and one- sixth of the policymakers in 
the Netherlands were recruited via an Internet panel. 
Figure 1 Example of a discrete choice experiment question.
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Payers had to have paid employment in an occupation 
in which they were (in)directly involved in the financing 
or payment of integrated care and/or care for persons 
with multimorbidity. Policymakers had to be (in)directly 
involved in policymaking or decision- making about 
healthcare, social care or welfare. In the other coun-
tries, payers and policymakers were recruited through 
our own networks and snowball sampling. Examples of 
payer organisations that were approached include health-
care insurance companies and departments of munic-
ipalities responsible for paying social care. Examples of 
policymakers include politicians, public servants from the 
ministries of health, ministries of social care, provincial 
or local governments and official governmental advisory 
bodies.
Patient and public involvement
The selection of the outcomes in the DCE was driven by 
the results of eight focus groups with in total 58 persons 
that had multiple chronic conditions. These focus 
groups were organised in 2016 in the countries partic-
ipating in the SELFIE project.15 As the participants of 
these focus groups frequently mentioned the importance 
of outcomes that went beyond the traditional health 
outcomes such as physical functioning, we included 
enjoyment of life, social relationships and participa-
tion and resilience to represent aspects of well- being 
and ‘positive health’.16 They also frequently mentioned 
negative experiences related to the single- disease focus 
of each provider, misaligned treatment goals and advices 
and fragmentation or duplication of care. That is the 
reason why ‘person- centredness’ and ‘continuity of care’ 
were identified as the two key elements of experience of 
care.
The selection of outcomes was further informed by 
national workshops with stakeholder representatives in 
these countries, an international advisory board meeting 
within the SELFIE project (see acknowledgement), a 
review of outcomes measured in the 17 integrated care 
programmes and a literature review on outcome measures 
of integrated care.17 In each country, two to four persons 
with multimorbidity and two to four informal caregivers 
were present at the national workshops. One patient 
representative and one representative from an informal 
caregiver organisation were present at the international 
advisory board meeting.
The online DCE survey was pilot tested in six elderly 
with multimorbidity from the Netherlands, including two 
think- aloud completions of the online questionnaire. 
Their feedback was used to improve the visual design and 
instructions of the questionnaire.
The results of the weight elicitation study were discussed 
in national stakeholder workshops and the international 
advisory board meetings of the SELFIE project, where 
both patients and informal caregivers were present. They 
were reimbursed for their travel and accommodation 
costs and did not receive other remuneration.
Ethics approval
We adhered to the national regulations regarding medical 
ethics approvals and waivers. Letters of Medical Ethics 
Approval of the MCDA’s and waivers were obtained from 
each country and forwarded to the European Commis-
sion as a Deliverable of the SELFIE project. All respon-
dents read the project information and provided online 
consent to take part before starting the online DCE survey.
Statistical analysis
A scale heterogeneity multinomial logit (S- MNL) 
model was used to analyse the responses by stakeholder 
group.18 19 This model contains respondent- specific scale 
parameters that account for differential choice vari-
ability caused by the fact that in some respondents the 
error- terms are more important relative to the observed 
attribute- coefficients than in others. This is often inter-
preted as a difference in choice consistency.20 The model 
also included a dummy variable to test whether respon-
dents were more likely to choose the integrated care 
programme that was presented left or right. As this was 
not the case, this dummy was not included in the final 
model.
The relative importance weight of each of the included 
attributes was calculated as the contribution of the attri-
bute’s best level coefficient (level 3) to the sum of all 
attributes’ best level coefficients. This was done because 
the weights, that will later be used in the MCDA’s of the 
integrated care programmes,6 need to represent the pref-
erence for the full swing from the worst to the best level 
of an attribute.
Differences in the mean preferences of stakeholder 
groups were evaluated using S- MNL models that analysed 
all stakeholder groups within a country simultaneously. 
Multiplicative interaction terms were used to assess the 
difference in preferences between the first stakeholder 
group (ie, patients with multimorbidity) and each of 
the other stakeholder groups. There is an indication of 
a difference when the 95% credible interval (CI) of the 
interaction term of a particular stakeholder group for a 
particular attribute does not contain 1.
All models were programmed in the BUGS language 
and estimated using OpenBUGS using Bayesian Markov 
Chain Monte Carlo (MCMC) methods (syntax provided 
in online supplemental box S2).
RESULTS
Respondents
Altogether, 5122 respondents completed the study, 
among which 1314 patients with multimorbidity. Of all 
patients who consented to complete the questionnaire, 
the proportion that completed all DCE questions was 
above 75%, except in Austria (67%). The mean time 
to complete the questionnaire was around 25 min (see 
online supplemental box S3).
Table 2 presents the characteristics of the respondents. 
Patients were older, less educated, in poorer health and 
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Table 2 Characteristics of the respondents included in the analysis
Patients Partners Professionals Payers Policymakers
Austria n=169 n=184 n=144 n=99 (combined)
Age mean (SD) 51.0 (15.0) 42.9 (14.7) 44.7 (8.8) 45.8 (10.7)
Gender (n,% female) 78 (46.2) 103 (56.0) 110 (77.5) 53 (53.5)
Educational level (n,%)*
  Low 15 (8.9) 10 (5.4) 0 (0) 0 (0)
  Medium 126 (74.5) 125 (67.9) 40 (28.1) 15 (15.2)
  High 28 (16.6) 49 (26.6) 102 (71.8) 81 (84.9)
General health (n,%)
  Poor or fair 87 (51.5) 30 (16.3) 4 (2.8) 2 (2)
  Good 67 (39.6) 70 (38.0) 33 (23.2) 23 (23.2)
  Very good or excellent 15 (8.9) 70 (45.7) 102 (71.8) 24 (74.7)
  Number of health problems (mean, SD) 3.4 (2.2) 2.0 (2.0) 0.7 (1.1) 0.6 (1.0)
Croatia n=168 n=169 n=103 n=73 (combined)
Age 43.1 (13.7) 42.6 (10.8) 44.4 (11.5) 45.3 (10.3)
Gender (n,% female) 104 (61.9) 96 (56.8) 79 (76.7) 62 (84.9)
Educational level (n,%)*
  Low 87 (51.8) 91 (53.9) 7 (6.8) 5 (6.8)
  Medium 39 (23.2) 33 (19.5) 38 (36.9) 26 (35.6)
  High 42 (25.0) 45 (26.7) 58 (56.4) 42 (57.5)
General health (n,%)
  Poor or fair 74 (44.1) 25 (14.8) 9 (8.8) 8 (10.9)
  Good 44 (26.2) 27 (16.0) 26 (25.2) 21 (28.8)
  Very good or excellent 50 (29.8) 117 (69.3) 68 (66.0) 44 (60.2)
  Number of health problems (mean, SD) 3.2 (2.3) 1.6 (1.6) 1.2 (1,3) 1.25 (1.6)
Germany n=160 n=208 n=170 n=110 (combined)
Age 52.7 (14.6) 46.8 (14.5) 42.4 (10.7) 45.6 (11.0)
Gender (n,% female) 77 (48.1) 102 (49.0) 123 (73.7) 65 (59.1)
Educational level (n,%)*
  Low 53 (33.2) 76 (36.5) 31 (18.6) 2 (1.8)
  Medium 85 (53.2) 90 (43.2) 68 (40.7) 36 (32.7)
  High 22 (13.9) 42 (20.2) 68 (40.7) 72 (65.4)
General health (n,%)
  Poor or fair 106 (66.3) 49 (23.5) 18 (10.8) 8 (7.3)
  Good 48 (30.0) 98 (47.1) 66 (39.5) 36 (32.7)
  Very good or excellent 6 (3.8) 61 (29.4) 83 (49.7) 66 (60.0)
  Number of health problems (mean, SD) 4.7 (2.5) 2.6 (2.7) 1.4 (1.7) 0.87 (1.2)
Hungary n=192 n=166 n=163 n=153 (combined)
Age 51.1 (14.1) 43.9 (14.3) 45.4 (10.9) 46.7 (10.8)
Gender (n,% female) 102 (53.1) 80 (48.2) 84 (51.5) 101 (66.0)
Educational level (n,%)*
  Low 65 (33.9) 51 (30.7) 1 (0.6) 3 (2.0)
  Medium 70 (36.5) 80 (48.2) 13 (8.0) 21 (13.7)
  High 57 (29.7) 35 (21.1) 149 (90.4) 129 (84.3)
General health (n,%)
  Poor or fair 120 (62.5) 44 (26.5) 23 (14.1) 18 (11.8)
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Patients Partners Professionals Payers Policymakers
  Good 61 (31.8) 71 (42.8) 46 (28.2) 50 (32.7)
  Very good or excellent 11 (5.7) 51 (30.7) 94 (57.7) 85 (55.6)
  Number of health problems (mean, SD) 4.0 (2.4) 2.1 (2.1) 1.1 (1.5) 1.1 (1.4)
Netherlands n=156 n=158 n=155 n=104 n=151
Age 60.4 (11.8) 52.2 (13.0) 42.0 (12.5) 42.8 (11.7) 46.3 (12.1)
Gender (n,% female) 77 (49.0) 81 (51.3) 86 (55.5) 48 (46.2) 95 (62.9)
Educational level (n,%)*
  Low 14 (9.0) 8 (5.1) 1 (0.6) 0 2 (1.3)
  Medium 70 (45.0) 76 (48.1) 48 (31.0) 1 (1.0) 0
  High 72 (46.2) 74 (46.8) 106 (68.3) 103 (99.1) 149 (89.7)
General health (n,%)
  Poor or fair 86 (55.2) 40 (25.3) 11 (7.1) 7 (6.7) 14 (9.2)
  Good 63 (40.4) 77 (48.7) 59 (38.1) 38 (36.5) 51 (33.8)
  Very good or excellent 7 (4.5) 42 (26.0) 85 (54.9) 59 (56.8) 86 (57.0)
  Number of health problems (mean, SD) 4.0 (1.9) 2.2 (2.5) 1.1 (1.5) 0.7 (1.0) 0.8 (1.2)
Norway n=156 n=156 n=162 n=122 n=180
Age 56.5 (14.7) 53.7 (12.9) 45.7 (10.7) 51.3 (10.3) 54.7 (13.2)
Gender (n,% female) 70 (44.9) 78 (50.00) 124 (76.5) 68 (55.7) 97 (53.9)
Educational level (n,%)*
  Low 11 (7.1) 1 (0.6) 2 (1.2) 1 (0.8) 0
  Medium 52 (33.3) 39 (25.0) 4 (2.5) 1 (0.8) 35 (19.4)
  High 93 (59.6) 116 (74.4) 156 (96.3) 120 (98.4) 145 (80.6)
  Poor or fair 78 (50.0) 38 (24.4) 8 (4.9) 5 (4.1) 17 (9.4)
  Good 47 (30.1) 64 (41.0) 33 (20.4) 17 (13.9) 50 (27.8)
  Very good or excellent 31 (19.9) 54 (34.6) 121 (74.7) 100 (82) 113 (62.8)
  Number of health problems (mean, SD) 3.6 (1.7) 2.2 (1.7) 1.1 (1.5) 0.79 (1.1) 1.5 (1.6)
Spain n=150 n=151 n=152
Age 62.8 (9.8) 55.3 (11.7) 40.8 (10.7)
Gender (n,% female) 65 (43.3) 103 (68.2) 40.76 (10.7)
Educational level (n,%)*
  Low 68 (45.4) 57 (37.8) 0
  Medium 39 (26) 54 (35.7) 30 (19.7)
  High 43 (28.7) 40 (26.4) 122 (80.3)
General health (n,%)
  Poor or fair 69 (46.0) 45 (29.8) 2 (1.3)
  Good 63 (42.0) 70 (46.4) 30 (19.7)
  Very good or excellent 18 (12.0) 36 (23.8) 120 (78.9)
  Number of health problems (mean, SD) 3.9 (2.5) 2.08 (1.7) 0.9 (1.0)
UK n=163 n=233 n=161 n=181 (combined)
Age 56.4 (14.4) 45 (13.8) 47.7 (10.8) 45.5 (11.0)
Gender (n,% female) 94 (57.7) 126 (54.1) 51 (31.7) 74 (40.9)
Educational level (n,%)*
  Low 60 (36.8) 60 (25.8) 0 3 (1.7)
  Medium 45 (27.6) 57 (24.5) 2 (1.2) 13 (7.2)
  High 58 (35.6) 116 (49.7) 159 (98.8) 165 (91.1)
Table 2 Continued
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less often had a paid job than the other stakeholders. 
The health of the partners and informal caregivers was 
less good than the health of the professionals, payers and 
policymakers. There was a relatively high proportion of 
women among the professionals. The top five of most 
frequently reported diseases (not risk factors) among 
patients across all countries included; (1) depression, 
anxiety or emotional difficulties; (2) chronic back pain 
or sciatica; (3) diabetes; (4) stomach problem, ulcer, 
gastritis or reflux; and (5) cardiovascular diseases (see 
online supplemental box S4).
Preferences of patients with multimorbidity
Table 3 shows the results of the regression analyses for 
the patients with multimorbidity. A positive regression 
coefficient means that respondents had a higher prefer-
ence for (ie, placed a higher weight on) that level of the 
outcome than level one. The larger the coefficient the 
stronger the preference. All outcomes contributed signifi-
cantly to patients’ choices, in the expected direction. The 
DCE- coefficients of outcome- levels two and three were 
almost all significantly different from level one. The coef-
ficients of level three were always higher than of level 
two, except for non- significant disordered levels of social 
relationships nd participation and person- centredness 
in Germany, continuity of care in Norway and Spain and 
costs in Spain.
The magnitude of the preference for the best level 
(level 3) was used as an indicator of the importance of 
the outcome measures. In all countries, except Hungary 
and Spain, enjoyment of life was valued most by patients, 
followed by either continuity of care (HR and DE), 
psychological well- being (NL and UK), physical func-
tioning (NO) or resilience (AT). In Hungary, patients 
assigned the highest value to continuity of care, whereas 
in Spain, patients assigned the highest value to psycho-
logical well- being, both followed by enjoyment of life. 
In six of the eight countries (not HR and HU), physical 
functioning was placed in the top three. Social relation-
ships and participation, person- centredness and costs 
were generally valued lower by the patients than other 
outcomes. The scale parameter was highest in Austria, 
indicating that the difference in choice consistency was 
greatest among the Austrian patients.
Within-country comparison of preferences of patients and 
other stakeholders
Figure 2 presents the relative preference weights, sorted 
by importance among patients with multimorbidity. 
Within countries, there was considerable agreement 
between patients and the other stakeholders, with enjoy-
ment of life mostly at the top and costs at the bottom. 
Nevertheless, there were differences.
As an indication of these differences, we counted the 
number of times that the 95% credibility intervals of the 
multiplicative interaction terms for stakeholder group 
and attribute excluded one (online supplemental box 
S5). Of all stakeholder groups, the preferences of profes-
sionals differed most often from the preferences of 
patients. These differences were most frequently related 
to physical functioning and person- centredness. Phys-
ical functioning was valued lower by professionals than 
patients in Austria, Germany, Netherlands, Norway and 
Spain. Person- centredness was valued higher by profes-
sionals than patients in Austria, Hungary, Germany and 
Spain.
Differences in relative weights between patients 
and payers/policymakers within a country were most 
frequently related to costs, which was more important 
to the latter in Austria, Germany, the Netherlands and 
Norway. However, the relative weight that they assigned to 
costs remained low. Payers and/or policymakers assigned 
lower values to continuity of care (HU, NL and NO), and 
resilience (DE, ES, HU and NL) than patients.
When the partners and other informal caregivers’ 
weights differed from the patients, that mostly related 
to physical functioning, which was valued lower than 
patients in Austria, Germany, Netherlands and Norway 
and higher than patients in Spain.
DISCUSSION
Main findings
This is the first international preference study among 
such a large number of persons with multimorbidity and 
other stakeholders involved in decision- making about 
person- centred integrated care. We found that there was 
considerable agreement between patients, partners and 
other informal caregivers, professionals, payers and poli-
cymakers. In all countries, they assigned the highest or 
Patients Partners Professionals Payers Policymakers
General health (n,%)
  Poor or fair 129 (79.2) 61 (26.2) 5 (3.1) 18 (10)
  Good 28 (17.2) 75 (32.2) 15 (9.3) 33 (18.2)
  Very good or excellent 6 (3.7) 97 (41.7) 141 (87.6) 130 (71.8)
  Number of health problems (mean, SD) 4.6 (2.4) 1.9 (2.1) 0.7 (1.0) 1.1 (1.6)
*low: no post- secondary education; high: Bachelor’s degree or higher.
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second highest value to enjoyment of life and the lowest 
or second lowest value to costs. Of the health and well- 
being outcomes, psychological well- being, physical func-
tioning and resilience were generally valued higher than 
social relationships and participation. Of the two experi-
ence outcomes, continuity of care was generally valued 
higher than person- centredness. Patients as well as the 
other stakeholders in the two Eastern European coun-
tries, Hungary and Croatia, assigned a relatively high 
value to continuity of care. Continuity of care also entered 
the top- three of professionals, payers and policymakers 
in Germany and Austria. Representatives from Eastern 
European countries suggested that the high preference 
assigned to continuity of care might illustrate problems 
Figure 2 Relative preferences for outcomes of all stakeholders, sorted by the preferences of patients with multimorbidity 
in each country (order of bars at each outcome: patients, partners and other informal caregivers, professionals, payers and 
policymakers). *95% credibility interval excludes 1, indicating that the stakeholder group differed from the patients with 
multimorbidity (see online supplemental box S5). The relative weight of the partners and other informal caregivers is 0 in 
Hungary. The Netherlands and Norway have five bars per attribute because they had respondents from all five stakeholder 
groups. The other countries combined the respondents from the payers and policymakers into one group and therefore have 
four bars per attribute, except for Spain which has three bars because they had not administered the questionnaire to payers 
and policymakers. Socialrelations &…, Social relations and participation.
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with access to care and long waiting lists in various parts 
of their healthcare systems. German and Austrian stake-
holders also pointed to a relation with capacity issues in 
especially the elderly care in their countries.
We also found indications of within- country differences 
in preferences between patients and other stakeholders. 
Of all stakeholder groups, professionals’ preferences 
differed most frequently from patients’ preferences and 
these differences most often pertained to physical func-
tioning and person- centredness. Professionals assigned 
lower values to physical functioning than patients in 
five countries, and higher values to person- centredness 
in four countries. Preference heterogeneity was also 
found for costs, which received higher values from payers 
and policymakers than from patients in four countries. 
However, the relative value of costs compared with the 
other outcomes remained low for these stakeholders as 
well. When discussing why costs commonly ranked last, 
even among payers and policymakers, stakeholder repre-
sentatives generally felt that this was in not in line with 
real world decision- making. The low value that patients 
assigned to costs might be related to the fact that they 
were informed that these costs did not have to be paid 
out- of- pocket. The low value assigned by payers and poli-
cymakers might be a reflection of the normative view-
point that costs should not play an important role when 
it comes to health. It might also be related to the chal-
lenging task of separating their professional role from the 
other roles they might have. Payers and policymakers can 
easily relate to, or might be, patients and informal care-
givers themselves.
Comparison with previous research
In contrast to most previous DCE studies of similar inter-
ventions, we defined the DCE attributes in terms of Triple 
Aim outcomes and not in terms of characteristics of the 
services provided. The choices made by the respondents 
indicated that they did make trade- offs between health, 
well- being and experience outcomes. That finding is in 
line with a recent study that also measured preferences 
for both health and well- being outcomes in the same valu-
ation procedure. They did so in response to the recog-
nition that the quality- adjusted life year (QALY) does 
not capture the full value of interventions that involve 
social care.21 Mulhern et al included the health domains 
of the EQ- 5D (EuroQol five- dimension questionnaire) 
and the well- being domains of the ASCOT (Adult Social 
Care Outcomes Toolkit) in the same DCE and found that 
the top- four of most valued outcomes by the Australian 
general public included one ASCOT domain, namely 
‘control over ones daily life’, which ranked fourth after 
the EQ- 5D domains pain and discomfort, mobility and 
anxiety/depression.21 They further found that social 
participation got the lowest value. This is in line with our 
study, where this outcome ended- up in the bottom- three 
in five countries (AT, DE, HR, HU and NL), based on 
patients’ values.
Muhlbacher and Bethge conducted a series of online 
DCE’s among US patients and German insurees (not only 
patients) that focussed on different features and building 
blocks of integrated service delivery.22 In contrast to our 
study, costs were an important attribute in both countries. 
It ranked highest in Germany and in the USA only ‘shared 
decision- making’ was slightly more important. The differ-
ence is most likely explained by the fact that costs were 
defined as out- of- pocket costs.
Burton et al, conducted a DCE that specifically aimed 
to value different aspects of person- centredness in UK 
patients with either chronic pain or chronic respiratory 
disease. They found that ‘taking account of the current 
living situation’, and ‘working with the patients on what 
they want to get from life’ were the most important 
aspects.23 Although our definition of person- centredness 
as ‘care that matches an individual’s needs, capabilities 
and preferences and where decisions are made jointly 
based on good information’ more or less incorporated 
these two aspects, that did not prevent this outcome to be 
ranked relatively low when it was compared with the other 
outcomes by the patients in Western European countries.
Limitations of the study
The first limitation is the cognitive challenge of completing 
a DCE. Respondents are expected to understand and 
interpret the definitions of the outcomes as provided. 
For that reason, we did not only explain the outcomes 
before the start of the DCE task, but also ensured that 
the definitions of the outcomes became visible in every 
choice task when respondents hovered the mouse over an 
outcome- heading. Respondents are further expected to 
consider all outcomes and make choices based on trade- 
offs between all outcomes. It has been reported in the 
literature that, although the majority of respondents does 
this, lower educated and less health literate respondents 
more often use simplified heuristics such as basing their 
choices on one or two high priority attributes.24 To reduce 
the complexity of the choices, we have used attribute- level 
overlap and colour coding. Nevertheless, the proportion 
of patients that found the questionnaire (very) diffi-
cult varied from 8.4% in Hungary to 35.3% in Norway. 
However, the observation that only a small proportion of 
patients in all countries completed the questionnaire in 
less than 5 min may illustrate their engagement in the 
DCE task. Excluding these patients from the analyses did 
not affect the results (available on request).
The second limitation is related to the assumption of 
preference independence underlying an MCDA,8 which 
means that the preference for a particular outcome is 
not influenced by the level of performance on the other 
outcomes. This was an important criterion when selecting 
the outcomes for the DCE. It was also the reason why 
enjoyment of life was framed positively (having pleasure 
and happiness in life) and psychological well- being was 
framed negatively (the absence of stress, worrying, listless-
ness, anxiety and feeling down). However, that does not 
avoid conceptual overlap entirely. We acknowledge that 
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enjoyment of life is a broad outcome measure that might 
be associated with some of the other outomes measures.
A last limitation concerns the generalisability of the 
results, especially of the persons with multimorbidity and 
the informal caregivers which were recruited through 
an existing Internet panel. Because of that, respon-
dents with lower levels of education, health literacy and 
health numeracy are likely to be under- represented in 
our study. This does not apply to Spain, where patients 
were recruited by professionals, which might have led to 
an over- representation of patients with high healthcare 
utilisation and informal caregivers with a higher burden 
of informal care.
Implications
First, the high preference for enjoyment of life, which 
was defined as having pleasure and happiness in life, 
underlines the importance of measuring outcomes 
beyond health to assess the wider value of integrated care 
programmes for people with multimorbidity. This is not 
often done, and certainly not routinely. Second, this high 
preference for enjoyment of life calls for more attention 
for social and mental support, something which is not 
exclusively provided by the healthcare sector. Patients 
care more about the big picture, that is, the pleasure and 
happiness in life, rather than the process of care, unless 
there is something clearly lacking in this process, such as 
continuity of care. Third, although it is good that many 
of the current integrated care programmes already pay 
a lot of attention to well- being and person- centredness, 
these efforts should not divert attention from improving 
physical functioning where possible. Fourth, the differ-
ences in relative preferences for physical functioning and 
person- centredness between patients and professionals 
in several countries stress the need for shared decision- 
making to prioritise services that improve outcomes 
most important to patients. Fifth, the existence of pref-
erence heterogeneity with respect to outcomes of inte-
grated care among stakeholders stresses the importance 
of informing decision- makers from multiple perspec-
tives. The MCDA’s of the 17 integrated care programmes 
that we are conducting are particularly suited for that.7 
These MCDA’s will be used to inform pragmatic, local 
and regional level decisions on different options to 
implement, adapt or scale- up existing integrated care 
programmes. In this context, the downside of an MCDA 
of using an outcome that does not allow a comparison 
between integrated care and other interventions, like the 
QALY, is acceptable. When such a comparison is required 
for system- level reimbursement decisions, it can be infor-
mative to compare the results of the MCDA to the results 
of a cost per QALY analysis.
CONCLUSION
Integrated care programmes aim to improve multiple 
outcomes. The most important outcome to patients with 
multimorbidity was the well- being outcome enjoyment 
of life, which calls for a greater involvement of the social 
and mental care sector. This also stresses the importance 
of including outcomes beyond health into the evaluation 
of these programmes. Process- related outcomes were 
less important to patients unless there were issues with 
the process, like the lack of continuity of care. The other 
stakeholders largely agreed with the preferences of the 
patients, although the preference heterogeneity with 
respect to physical functioning and person- centredness 
underlines the importance of shared decisionmaking 
between patients with multimorbidity and professionals.
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Online supplementary file  
 
Box S1. Original, literature-based, priors. 
 DCE-Level 
DCE-Attribute Worst (1) 
Average (2) 
Mean (SD) 
Best (3) 
Mean (SD) 
Physical functioning Reference 0.30 (0.12) 0.60 (0.23) 
Psychological wellbeing Reference 0.20 (0.08) 0.40 (0.16) 
Social relations & participation Reference 0.25 (0.10) 0.45 (0.18) 
Enjoyment of life Reference 0.20 (0.08) 0.40 (0.16) 
Resilience Reference 0.20 (0.08) 0.40 (0.16) 
Person-centeredness Reference 0.10 (0.04) 0.25 (0.10) 
Continuity of care Reference 0.15 (0.06) 0.30 (0.12) 
Total costs Reference 0.15 (0.06) 0.35 (0.14) 
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Box S2. Example of OpenBUGS model code for the S-MNL models. 
All models were programmed in the BUGS language and estimated using OpenBUGS using Bayesian 
Markov Chain Monte Carlo (MCMC) methods. This entails selecting prior distributions for the unknown 
model parameters and updating these via the likelihood of the observed choice data. The specification 
of the priors and the model codes are presented below. All estimations used 10,000 MCMC iterations to 
let three chains converge from divergent starting points and another 20,000 MCMC iterations to reliably 
approximate the posterior distributions of the parameters. Convergence was evaluated based on a 
visual inspection of the MCMC chains and the diagnostics as included in the OpenBUGS software. 
Custom MCMC slice samplers were used for the GMNL-scale and the rho parameters; these are 
available from the authors upon request.  
 
 
Model #1. Separate S-MNL models for each stakeholder group  
 
model { 
 
 # N  = number of respondents   
 # N1 = number of respondents in P1 group 
 # N2 = number of respondents in P2 group 
 # N3 = number of respondents in P3 group 
 # N4 = number of respondents in P4 group 
 # T  = number of choice tasks 
 # V  = number of parameters  
 
 # likelihood of pairwise choice tasks 
 for (n in 1:N){  
   for(t in 1:T){ 
     Y[n,t] <- 0 
     Y[n,t] ~ dcat2(phi[n,t])  
 }} 
  
 # utility function P1 
 for (n in 1:N1){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n]      
     attr1[n,t] <- (beta[1,1]  * X[n,t,1]  + beta[1,2]  * X[n,t,2] )  
     attr2[n,t] <- (beta[1,3]  * X[n,t,3]  + beta[1,4]  * X[n,t,4] ) 
     attr3[n,t] <- (beta[1,5]  * X[n,t,5]  + beta[1,6]  * X[n,t,6] )  
     attr4[n,t] <- (beta[1,7]  * X[n,t,7]  + beta[1,8]  * X[n,t,8] )        
     attr5[n,t] <- (beta[1,9]  * X[n,t,9]  + beta[1,10] * X[n,t,10]) 
     attr6[n,t] <- (beta[1,11] * X[n,t,11] + beta[1,12] * X[n,t,12])  
     attr7[n,t] <- (beta[1,13] * X[n,t,13] + beta[1,14] * X[n,t,14])  
     attr8[n,t] <- (beta[1,15] * X[n,t,15] + beta[1,16] * X[n,t,16])          
 }} 
  
 # utility function P2 
 for (n in N1+1:N1+N2){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n]      
     attr1[n,t] <- (beta[2,1] * X[n,t,1]  + beta[2,2] * X[n,t,2] )   
     attr2[n,t] <- (beta[2,3] * X[n,t,3]  + beta[2,4] * X[n,t,4] )  
     attr3[n,t] <- (beta[2,5] * X[n,t,5]  + beta[2,6] * X[n,t,6] )  
     attr4[n,t] <- (beta[2,7] * X[n,t,7]  + beta[2,8] * X[n,t,8] )         
     attr5[n,t] <- (beta[2,9] * X[n,t,9]  + beta[2,10]* X[n,t,10])   
     attr6[n,t] <- (beta[2,11]* X[n,t,11] + beta[2,12]* X[n,t,12])   
     attr7[n,t] <- (beta[2,13]* X[n,t,13] + beta[2,14]* X[n,t,14])   
     attr8[n,t] <- (beta[2,15]* X[n,t,15] + beta[2,16]* X[n,t,16])    
 }} 
  
 
 # utility function P3 
 for (n in N1+N2+1:N1+N2+N3){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n]  
     attr1[n,t] <- (beta[3,1] * X[n,t,1]  + beta[3,2] * X[n,t,2] )   
     attr2[n,t] <- (beta[3,3] * X[n,t,3]  + beta[3,4] * X[n,t,4] )  
     attr3[n,t] <- (beta[3,5] * X[n,t,5]  + beta[3,6] * X[n,t,6] )  
     attr4[n,t] <- (beta[3,7] * X[n,t,7]  + beta[3,8] * X[n,t,8] )         
     attr5[n,t] <- (beta[3,9] * X[n,t,9]  + beta[3,10]* X[n,t,10])   
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     attr6[n,t] <- (beta[3,11]* X[n,t,11] + beta[3,12]* X[n,t,12])   
     attr7[n,t] <- (beta[3,13]* X[n,t,13] + beta[3,14]* X[n,t,14])   
     attr8[n,t] <- (beta[3,15]* X[n,t,15] + beta[3,16]* X[n,t,16])    
 }} 
  
 # utility function P4  
 for (n in N1+N2+N3+1:N1+N2+N3+N4){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n]     
     attr1[n,t] <- (beta[4,1] * X[n,t,1]  + beta[4,2] * X[n,t,2] )  
     attr2[n,t] <- (beta[4,3] * X[n,t,3]  + beta[4,4] * X[n,t,4] )  
     attr3[n,t] <- (beta[4,5] * X[n,t,5]  + beta[4,6] * X[n,t,6] )   
     attr4[n,t] <- (beta[4,7] * X[n,t,7]  + beta[4,8] * X[n,t,8] )         
     attr5[n,t] <- (beta[4,9] * X[n,t,9]  + beta[4,10]* X[n,t,10])   
     attr6[n,t] <- (beta[4,11]* X[n,t,11] + beta[4,12]* X[n,t,12])   
     attr7[n,t] <- (beta[4,13]* X[n,t,13] + beta[4,14]* X[n,t,14])   
     attr8[n,t] <- (beta[4,15]* X[n,t,15] + beta[4,16]* X[n,t,16])    
 }} 
   
 # priors on beta's 
 beta[1,1:V] ~ dmnorm(zeros[], tau_beta[,]) 
 beta[2,1:V] ~ dmnorm(zeros[], tau_beta[,]) 
 beta[3,1:V] ~ dmnorm(zeros[], tau_beta[,]) 
 beta[4,1:V] ~ dmnorm(zeros[], tau_beta[,]) 
 
 for (b in 1:V){  
  zeros[b] <- 0 
  for (bb in 1:V){ 
    tau_beta[b,bb] <- equals(b,bb)/100 
 }} 
  
 # priors on gmnl_scale parameters 
 # subject to a mean-of-one constraint for identification   
 gmnl_scale[1:N1] ~ dGMNLscale(tau[1]) 
 gmnl_scale[N1+1:N1+N2] ~ dGMNLscale(tau[2]) 
 gmnl_scale[N1+N2+1:N1+N2+N3] ~ dGMNLscale(tau[3]) 
 gmnl_scale[N1+N2+N3+1:N1+N2+N3+N4] ~ dGMNLscale(tau[4]) 
 # this implies that SD(tau) is restricted between 0.01 and 10 
 for (group in 1:4){ 
   tau[group] ~ dunif(0.01,10000) 
 } 
 
 # monitor SD of gmnl_scale parameters 
 for (group in 1:4){ 
   gmnl_SD[group] <- sqrt( 1.0/ tau[group] ) 
 } 
 
 # monitor attribute importances 
 for (group in 1:4){ 
   weight[group,1] <- beta[group,2]    
   weight[group,2] <- beta[group,4]    
   weight[group,3] <- beta[group,6]    
   weight[group,4] <- beta[group,8]    
   weight[group,5] <- beta[group,10]    
   weight[group,6] <- beta[group,12]   
   weight[group,7] <- beta[group,14]   
   weight[group,8] <- beta[group,16]   
   total_weight[group] <- sum(weight[group,]) 
   attr_importance[group,1] <- weight[group,1] / total_weight[group] 
   attr_importance[group,2] <- weight[group,2] / total_weight[group] 
   attr_importance[group,3] <- weight[group,3] / total_weight[group] 
   attr_importance[group,4] <- weight[group,4] / total_weight[group] 
   attr_importance[group,5] <- weight[group,5] / total_weight[group] 
   attr_importance[group,6] <- weight[group,6] / total_weight[group] 
   attr_importance[group,7] <- weight[group,7] / total_weight[group] 
   attr_importance[group,8] <- weight[group,8] / total_weight[group] 
 }            
} 
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Model #2. Combined S-MNL model with multiplicative attribute-importance parameters 
  
model { 
 
 # likelihood of pairwise choice tasks 
 for (n in 1:N){  
   for(t in 1:T){ 
     Y[n,t] <- 0 
     Y[n,t] ~ dcat2(phi[n,t])  
 }} 
  
 # utility function P1 
 for (n in 1:N1){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n] * scale[1]      
     attr1[n,t] <- (beta[1]  * X[n,t,1]  + beta[2]  * X[n,t,2] )  
     attr2[n,t] <- (beta[3]  * X[n,t,3]  + beta[4]  * X[n,t,4] ) 
     attr3[n,t] <- (beta[5]  * X[n,t,5]  + beta[6]  * X[n,t,6] )  
     attr4[n,t] <- (beta[7]  * X[n,t,7]  + beta[8]  * X[n,t,8] )        
     attr5[n,t] <- (beta[9]  * X[n,t,9]  + beta[10] * X[n,t,10]) 
     attr6[n,t] <- (beta[11] * X[n,t,11] + beta[12] * X[n,t,12])  
     attr7[n,t] <- (beta[13] * X[n,t,13] + beta[14] * X[n,t,14])  
     attr8[n,t] <- (beta[15] * X[n,t,15] + beta[16] * X[n,t,16])          
 }} 
  
 # utility function P2 
 for (n in N1+1:N1+N2){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n] * scale[2]      
     attr1[n,t] <- (beta[1] * X[n,t,1]  + beta[2] * X[n,t,2] ) * rho[2,1]  
     attr2[n,t] <- (beta[3] * X[n,t,3]  + beta[4] * X[n,t,4] ) * rho[2,2] 
     attr3[n,t] <- (beta[5] * X[n,t,5]  + beta[6] * X[n,t,6] ) * rho[2,3] 
     attr4[n,t] <- (beta[7] * X[n,t,7]  + beta[8] * X[n,t,8] ) * rho[2,4]        
     attr5[n,t] <- (beta[9] * X[n,t,9]  + beta[10]* X[n,t,10]) * rho[2,5]  
     attr6[n,t] <- (beta[11]* X[n,t,11] + beta[12]* X[n,t,12]) * rho[2,6]  
     attr7[n,t] <- (beta[13]* X[n,t,13] + beta[14]* X[n,t,14]) * rho[2,7]  
     attr8[n,t] <- (beta[15]* X[n,t,15] + beta[16]* X[n,t,16]) * rho[2,8]   
 }} 
  
 
 # utility function P3 
 for (n in N1+N2+1:N1+N2+N3){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n] * scale[3] 
     attr1[n,t] <- (beta[1] * X[n,t,1]  + beta[2] * X[n,t,2] ) * rho[3,1]  
     attr2[n,t] <- (beta[3] * X[n,t,3]  + beta[4] * X[n,t,4] ) * rho[3,2] 
     attr3[n,t] <- (beta[5] * X[n,t,5]  + beta[6] * X[n,t,6] ) * rho[3,3] 
     attr4[n,t] <- (beta[7] * X[n,t,7]  + beta[8] * X[n,t,8] ) * rho[3,4]        
     attr5[n,t] <- (beta[9] * X[n,t,9]  + beta[10]* X[n,t,10]) * rho[3,5]  
     attr6[n,t] <- (beta[11]* X[n,t,11] + beta[12]* X[n,t,12]) * rho[3,6]  
     attr7[n,t] <- (beta[13]* X[n,t,13] + beta[14]* X[n,t,14]) * rho[3,7]  
     attr8[n,t] <- (beta[15]* X[n,t,15] + beta[16]* X[n,t,16]) * rho[3,8]   
 }} 
  
 # utility function P4  
 for (n in N1+N2+N3+1:N1+N2+N3+N4){  
   for (t in 1:T){ 
     phi[n,t]  <- (attr1[n,t] + attr2[n,t] + attr3[n,t] + attr4[n,t] + attr5[n,t] + 
            attr6[n,t] + attr7[n,t] + attr8[n,t]) * gmnl_scale[n] * scale[4]     
     attr1[n,t] <- (beta[1] * X[n,t,1]  + beta[2] * X[n,t,2] ) * rho[4,1]  
     attr2[n,t] <- (beta[3] * X[n,t,3]  + beta[4] * X[n,t,4] ) * rho[4,2] 
     attr3[n,t] <- (beta[5] * X[n,t,5]  + beta[6] * X[n,t,6] ) * rho[4,3] 
     attr4[n,t] <- (beta[7] * X[n,t,7]  + beta[8] * X[n,t,8] ) * rho[4,4]        
     attr5[n,t] <- (beta[9] * X[n,t,9]  + beta[10]* X[n,t,10]) * rho[4,5]  
     attr6[n,t] <- (beta[11]* X[n,t,11] + beta[12]* X[n,t,12]) * rho[4,6]  
     attr7[n,t] <- (beta[13]* X[n,t,13] + beta[14]* X[n,t,14]) * rho[4,7]  
     attr8[n,t] <- (beta[15]* X[n,t,15] + beta[16]* X[n,t,16]) * rho[4,8]   
 }} 
   
 # priors on beta's 
 beta[1:V] ~ dmnorm(zeros[], tau_beta[,]) 
 
 for (b in 1:V){  
  zeros[b] <- 0 
  for (bb in 1:V){ 
    tau_beta[b,bb] <- equals(b,bb)/100 
 }} 
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 # priors on gmnl_scale parameters 
 # subject to a mean-of-one constraint for identification   
 gmnl_scale[1:N1] ~ dGMNLscale(tau[1]) 
 gmnl_scale[N1+1:N1+N2] ~ dGMNLscale(tau[2]) 
 gmnl_scale[N1+N2+1:N1+N2+N3] ~ dGMNLscale(tau[3]) 
 gmnl_scale[N1+N2+N3+1:N1+N2+N3+N4] ~ dGMNLscale(tau[4]) 
 # this implies that SD(tau) is restricted between 0.01 and 10 
 for (group in 1:4){ 
   tau[group] ~ dunif(0.01,10000) 
 } 
 
 # monitor SD of gmnl_scale parameters 
 for (group in 1:4){ 
   gmnl_SD[group] <- sqrt( 1.0/ tau[group] ) 
 } 
 
 # priors on relative attribute importance parameters (P1 is the base-case sample) 
 # subject to a mean-of-one constraint for identification   
 # see Jonker et al. 2019, this prior places 95% of the prior mass between 0.4 and 2.0  
  for (att in 1:8){  
   rho[1,att] <- 1  
 } 
 for (group in 2:4){  
   rho[group,1:8] ~ dscale(6.25)  
 } 
 
 # priors on the relative scale parameters (P1 is the base-case sample) 
 # see Jonker et al. 2019, this prior places 95% of the prior mass between 0.4 and 2.0 
 scale[1] <- 1   
 for (group in 2:4) {  
   scale[group] ~ dlnorm(-0.08,6.25)C(0.1,10)  
 } 
 # the truncation normalizing constant in the log prior does not need to be explicitly  
 # evaluated since the truncation boundaries remain constant during MCMC sampling. Hence    
 # sensoring C() is sufficient and can be used instead of truncation T(), which isn’t implemented 
 
 
 # monitor attribute importances 
 for (group in 1:4){ 
   weight[group,1] <- beta[2]  * rho[group,1] 
   weight[group,2] <- beta[4]  * rho[group,2] 
   weight[group,3] <- beta[6]  * rho[group,3] 
   weight[group,4] <- beta[8]  * rho[group,4] 
   weight[group,5] <- beta[10] * rho[group,5]  
   weight[group,6] <- beta[12] * rho[group,6] 
   weight[group,7] <- beta[14] * rho[group,7] 
   weight[group,8] <- beta[16] * rho[group,8] 
   total_weight[group] <- sum(weight[group,]) 
   attr_importance[group,1] <- weight[group,1] / total_weight[group] 
   attr_importance[group,2] <- weight[group,2] / total_weight[group] 
   attr_importance[group,3] <- weight[group,3] / total_weight[group] 
   attr_importance[group,4] <- weight[group,4] / total_weight[group] 
   attr_importance[group,5] <- weight[group,5] / total_weight[group] 
   attr_importance[group,6] <- weight[group,6] / total_weight[group] 
   attr_importance[group,7] <- weight[group,7] / total_weight[group] 
   attr_importance[group,8] <- weight[group,8] / total_weight[group] 
 }            
} 
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Box S3. Indicators of questionnaire completion and perceived difficulty 
Completion AT HR HU DE NL NO ES UK 
Gave informed 
consent 
253 229 283 207 207 203 150 208 
Finished all DCE 
scenario’s (%) 
170 
(67) 
173 
(76) 
194 
(93) 
166 
(80) 
160 
(77) 
158 
(78) 
150 
(100) 
165 
(79) 
Finished entire 
questionnaire 
169 
(68) 
168 
(73) 
192 
(68) 
160 
(77) 
156 
(75) 
156 
(77) 
150 
(100) 
163 
(78) 
Mean  (SD) time to 
completion entire 
questionnaire 
22.87 
(21.73) 
22.43 
(37.68) 
20.27 
(14.88) 
26.21 
(48.74) 
26.21 
(48.74) 
27.33 
(27.90) 
26.96 
(10.12) 
24.68 
(62.64) 
Required >5 minutes 
(%)* 
167 
(99) 
160 
(95) 
180 
(94) 
158 
(99) 
156 
(100) 
152 
(97) 
149 
(99) 
155 
(95) 
Self-reported 
difficulty 
        
Very easy 16 
(9.5) 
11 
(6.5) 
23 
(12.0) 
14 
(8.8) 
3 
(1.9) 
2 
(1.3) 
1 
(0.7) 
31 
(19.0) 
Easy 39 
(23.1) 
30 
(17.9) 
71 
(37.0) 
33 
(20.6) 
40 
(25.6) 
20 
(12.8) 
36 
(24.0) 
45 
(27.6) 
Not too easy, not too 
difficult 
85 
(50.3) 
70 
(41.7) 
75 
(39.1) 
84 
(52.5) 
74 
(47.4) 
79 
(50.6) 
71 
(47.3) 
63 
(38.7) 
Difficult 25 
(14.8) 
44 
(26.2) 
22 
(11.5) 
24 
(15.0) 
31 
(19.9) 
48 
(30.8) 
30 
(20.0) 
22 
(13.5) 
Very difficult 4 
(2.4) 
13 
(7.7) 
1 
(0.5) 
5 
(3.1) 
8 
(5.1) 
7 
(4.5) 
12 
(8.0) 
2 
(1.2) 
* As % of those that completed the entire questionnaire 
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Box S4. Patients’ self-reported health problems.  
N (%) AT HR HU DE NL NO ES UK 
I prefer not to answer 4 
(2.4) 
10 
(6.0) 
3 
(1.6) 
4 
(1.9) 
2 
(1.3) 
0  
(0) 
6  
(4) 
3  
(1.8) 
Asthma 20 
(11.8) 
19 
(11.3) 
26 
(13.5) 
18 
(8.7) 
19 
(12.2) 
29 
(18.6) 
6  
(4) 
41 
(25.2) 
Cancer during the past five 
years 
10 
(5.9) 
5 
(3.0) 
11 
(5.7) 
4 
(1.9) 
10 
(6.4) 
11 
(7.1) 
18 
(12) 
10 
(6.1) 
Chronic back pain or sciatica 69 
(40.8) 
54 
(32.1) 
32 
(16.7) 
47 
(22.6) 
32 
(20.5) 
29 
(18.6) 
50 
(33.3) 
51 
(31.3) 
Chronic bronchitis, COPD or 
emphysema 
32 
(18.9) 
8 
(4.8) 
9 
(4.7) 
14 
(6.7) 
26 
(16.7) 
7  
(4.5) 
29 
(19.3) 
28 
(17.2) 
Chronic kidney disease 4 
(2.4) 
6 
(3.6) 
8 
(4.2) 
9 
(4.3) 
4 
(2.6) 
0  
(0) 
9  
(6) 
8  
(4.9) 
Cognitive problems, memory 
loss, dementia, Alzheimer’s 
3 
(1.8) 
0  
(0) 
2 
(1.0) 
2 
(1.0) 
6 
(3.8) 
6  
(3.9) 
0  
(0) 
4  
(2.5) 
Colon problem, irritable bowel 
or colitis 
28 
(16.6) 
18 
(10.7) 
15 
(7.8) 
9 
(4.3) 
34 
(21.8) 
31 
(19.9) 
7 
(4.7) 
32 
(19.6) 
Congestive heart failure 9 
(5.3) 
1 
(0.6) 
4 
(2.2) 
8 
(3.8) 
9 
(5.8) 
5  
(3.2) 
9  
(6) 
3  
(1.8) 
Depression, anxiety or 
emotional difficulties 
63 
(37.3) 
47 
(28.0) 
63 
(32.8) 
36 
(17.3) 
29 
(18.6) 
32 
(20.5) 
36 
(24) 
70 
(42.9) 
Diabetes 29 
(17.2) 
17 
(10.1) 
43 
(22.4) 
35 
(16.8) 
36 
(23.1) 
16 
(10.3) 
26 
(17.3) 
45 
(27.6) 
Hard of hearing 18 
(10.7) 
16 
(9.5) 
27 
(14.1) 
14 
(6.7) 
28 
(17.9) 
35 
(22.4) 
17 
(11.3) 
18 
(11.0) 
Heart disease, angina (chest 
pain from heart problem), heart 
attack, bypass surgery or 
angioplasty 
20 
(11.8) 
19 
(11.3) 
20 
(10.4) 
10 
(4.8) 
26 
(16.7) 
15 
(9.6) 
19 
(12.7) 
28 
(17.2) 
High blood pressure 67 
(39.6) 
40 
(23.8) 
95 
(49.5) 
68 
(32.7) 
61 
(39.1) 
58 
(37.2) 
50 
(33.3) 
64 
(39.3) 
High cholesterol 34 
(20.1) 
27 
(16.1) 
46 
(24.0) 
40 
(19.2) 
47 
(30.1) 
38 
(24.4) 
45 
(30) 
47 
(28.8) 
Osteoarthritis (not rheumatoid 
arthritis) 
5 
(3.0) 
9 
(5.4) 
59 
(30.7) 
7 
(3.4) 
33 
(21.2) 
46 
(29.5) 
7 
(4.7) 
43 
(26.4) 
Osteoporosis (brittle bones) 15 
(8.9) 
11 
(6.5) 
13 
(6.8) 
6 
(2.9) 
10 
(6.4) 
9  
(5.8) 
21 
(14) 
16 
(9.8) 
Overweight 55 
(32.5) 
46 
(27.4) 
68 
(35.4) 
56 
(26.9) 
49 
(31.4) 
51 
(32.7) 
47 
(31.3) 
47 
(28.8) 
Poor circulation in your legs 22 
(13.0) 
27 
(16.1) 
49 
(25.5) 
17 
(8.2) 
21 
(13.5) 
22 
(14.1) 
35 
(23.3) 
23 
(14.1) 
Rheumatoid arthritis 25 
(14.8) 
10 
(6.0) 
19 
(9.9) 
17 
(8.2) 
21 
(13.5) 
10 
(6.4) 
12  
(8) 
19 
(11.7) 
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Rheumatic disease, fibromyalgia 
or lupus 
14 
(8.3) 
5 
(3.0) 
13 
(6.8) 
15 
(7.2) 
11 
(7.1) 
16 
(10.3) 
12  
(8) 
11 
(6.7) 
 Stomach problem, ulcer, 
gastritis or reflux 
29 
(17.2) 
27 
(16.1) 
46 
(24.0) 
25 
(12.0) 
21 
(13.5) 
24 
(15.4) 
22 
(14.7) 
28 
(17.2) 
Stroke 4 
(2.4) 
4 
(2.4) 
8 
(4.2) 
10 
(4.8) 
3 
(1.9) 
2  
(1.3) 
7 
(4.7) 
9  
(5.5) 
Thyroid disorder 30 
(17.8) 
33 
(19.6) 
23 
(12.0) 
27 
(13.0) 
14 
(9.0) 
18 
(11.5) 
10 
(6.7) 
16 
(9.8) 
Vision problem 26 
(15.4) 
50 
(29.8) 
28 
(14.6) 
29 
(13.9) 
28 
(17.9) 
21 
(13.5) 
56 
(37.3) 
18 
(11.0) 
No health problems 1 
(0.6) 
6 
(3.6) 
0 
(0.0) 
28 
(13.5) 
2 
(1.3) 
0  
(0) 
3  
(2) 
0 
(0) 
Other health problems 39 
(23.1) 
30 
(17.9) 
31 
(16.2) 
16 
(7.7) 
39 
(25.0) 
34 
(21.8) 
31 
(20.7) 
73 
(44.8) 
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Supplementary file Box S5. Coefficients and 95% credibility intervals (CI) of the multiplicative interaction terms to investigate differences between patients (P1) 
and the other stakeholder groups, i.e., Partners & other informal caregivers (P2), professionals (P3), payers (P4), and policy makers (P5). The bold cells indicate the 
95% CI of the multiplicative interaction terms for stakeholder group and attribute that excluded 1. 
 
  P2 vs P1 P3 vs P1 P4/5 vs P1 P4 vs P1 P5 vs P1 
  
coefficient 95% CI coefficient 95% CI coefficient 95% CI coefficient 95% CI coefficient 95% CI 
AT Physical functioning 0.74 0.52 1.00 0.64 0.48 0.82 0.65 0.48 0.87 
      
 
Psych.l well-being 1.25 0.95 1.62 1.14 0.91 1.42 1.06 0.82 1.35 
      
 
Social relations & part 0.93 0.62 1.29 1.16 0.92 1.45 1.09 0.83 1.40 
      
 
Enjoyment of life 1.11 0.88 1.38 0.94 0.78 1.11 0.89 0.72 1.09 
      
 
Resilience 0.98 0.74 1.24 0.87 0.70 1.07 0.79 0.61 1.00 
      
 
Person-centeredness 1.27 0.79 1.83 1.45 1.07 1.88 1.16 0.79 1.58 
      
 
Continuity of care 1.01 0.76 1.30 1.17 0.94 1.41 1.07 0.83 1.34 
      
 
Total costs 0.71 0.40 1.10 0.64 0.39 0.97 1.29 0.87 1.83 
      
                 
DE Physical functioning 0.56 0.34 0.83 0.52 0.38 0.69 0.77 0.57 1.00 
      
 
Psychological well-
being 
0.81 0.50 1.22 1.04 0.77 1.40 1.19 0.88 1.58 
      
 
Social relations & part 0.98 0.63 1.40 1.01 0.77 1.31 0.88 0.64 1.16 
      
 
Enjoyment of life 1.07 0.84 1.35 0.80 0.66 0.96 0.78 0.63 0.96 
      
 
Resilience 1.00 0.74 1.29 0.78 0.63 0.96 0.73 0.57 0.91 
      
 
Person-centeredness 1.09 0.66 1.64 1.70 1.28 2.17 1.17 0.82 1.59 
      
 
Continuity of care 1.32 1.00 1.69 1.19 0.98 1.44 0.89 0.69 1.12 
      
 
Total costs 1.16 0.66 1.72 0.95 0.65 1.36 1.59 1.15 2.15 
      
                 
ES Physical functioning 1.23 1.06 1.44 0.51 0.41 0.64 
         
 
Psychological well-
being 
0.77 0.64 0.91 0.73 0.60 0.87 
         
 
Social relations & part 1.01 0.84 1.20 0.73 0.60 0.88 
         
 
Enjoyment of life 0.87 0.72 1.03 0.96 0.80 1.13 
         
 
Resilience 1.01 0.83 1.22 0.80 0.65 0.99 
         
 
Person-centeredness 1.43 1.16 1.75 1.64 1.35 1.96 
         
 
Continuity of care 0.95 0.70 1.25 1.12 0.86 1.45 
         
 
Total costs 0.73 0.43 1.11 1.50 1.06 2.09 
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HR Physical functioning 0.87 0.62 1.16 0.86 0.59 1.14 1.20 0.89 1.55 
      
 
Psychological well-
being 
1.04 0.83 1.30 1.07 0.84 1.33 0.83 0.62 1.06 
      
 
Social relations & part 0.92 0.70 1.17 1.00 0.77 1.26 0.91 0.67 1.17 
      
 
Enjoyment of life 1.01 0.83 1.21 1.22 1.02 1.45 1.01 0.82 1.23 
      
 
Resilience 0.81 0.63 1.01 0.81 0.63 1.01 1.03 0.81 1.29 
      
 
Person-centeredness 1.14 0.91 1.39 1.08 0.86 1.33 0.95 0.73 1.19 
      
 
Continuity of care 1.20 0.98 1.44 1.26 1.03 1.51 0.87 0.68 1.10 
      
 
Total costs 1.00 0.55 1.59 0.70 0.36 1.18 1.20 0.67 1.91 
      
                 
HU Physical functioning 0.77 0.53 1.06 0.89 0.67 1.16 0.87 0.67 1.10 
      
 
Psychological well-
being 
1.57 1.14 2.08 1.16 0.84 1.55 1.16 0.87 1.52 
      
 
Social relations & part 1.01 0.70 1.35 0.93 0.69 1.22 1.05 0.82 1.32 
      
 
Enjoyment of life 1.30 0.98 1.66 1.14 0.89 1.42 1.04 0.84 1.29 
      
 
Resilience 0.80 0.57 1.08 0.77 0.58 1.01 0.65 0.50 0.84 
      
 
Person-centeredness 0.90 0.64 1.19 1.32 1.04 1.66 1.01 0.79 1.25 
      
 
Continuity of care 1.05 0.83 1.30 0.95 0.77 1.15 0.81 0.66 0.97 
      
 
Total costs 0.60 0.29 1.07 0.83 0.44 1.32 1.42 0.91 2.09 
      
                 
NL Physical functioning 0.77 0.63 0.92 0.73 0.61 0.87 
   
0.92 0.79 1.06 0.87 0.74 1.00 
 
Psychological well-
being 
0.91 0.74 1.12 1.10 0.93 1.32 
   
1.12 0.94 1.34 0.91 0.77 1.09 
 
Social relations & part 0.97 0.76 1.22 1.15 0.96 1.38 
   
1.09 0.90 1.32 1.09 0.91 1.30 
 
Enjoyment of life 1.11 0.96 1.27 0.99 0.87 1.13 
   
1.05 0.92 1.20 0.96 0.85 1.09 
 
Resilience 0.95 0.81 1.11 0.83 0.71 0.96 
   
0.77 0.65 0.89 0.93 0.81 1.06 
 
Person-centeredness 1.05 0.81 1.33 1.02 0.82 1.26 
   
0.80 0.61 1.01 0.98 0.78 1.21 
 
Continuity of care 1.07 0.85 1.31 0.91 0.72 1.10 
   
0.73 0.56 0.91 0.82 0.66 1.00 
 
Total costs 1.16 0.81 1.55 1.27 0.96 1.62 
   
1.53 1.19 1.93 1.43 1.12 1.82 
                 
NO Physical functioning 0.66 0.53 0.80 0.71 0.60 0.83 
   
0.77 0.64 0.90 0.63 0.53 0.75 
 
Psychological well-
being 
1.08 0.90 1.27 0.98 0.84 1.14 
   
0.87 0.72 1.03 0.86 0.73 1.01 
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Social relations & part 1.32 1.09 1.56 1.19 1.01 1.40 
   
0.97 0.79 1.17 1.18 0.98 1.39 
 
Enjoyment of life 1.12 0.94 1.32 1.11 0.94 1.29 
   
1.04 0.87 1.23 0.99 0.84 1.15 
 
Resilience 0.83 0.64 1.06 1.00 0.84 1.19 
   
1.09 0.90 1.32 1.07 0.88 1.29 
 
Person-centeredness 1.25 0.86 1.66 1.08 0.79 1.41 
   
0.79 0.51 1.09 1.10 0.81 1.44 
 
Continuity of care 0.86 0.67 1.09 0.92 0.74 1.12 
   
0.72 0.57 0.92 1.03 0.84 1.26 
 
Total costs 0.88 0.46 1.41 1.02 0.62 1.48 
   
1.77 1.25 2.36 1.13 0.71 1.66 
                 
UK Physical functioning 0.82 0.63 1.03 0.94 0.77 1.14 0.94 0.76 1.15 
      
 
Psychological well-
being 
1.17 0.95 1.42 1.00 0.82 1.20 1.07 0.85 1.31 
      
 
Social relations & part 1.06 0.84 1.29 1.03 0.83 1.25 1.01 0.79 1.25 
      
 
Enjoyment of life 1.15 0.97 1.34 0.98 0.83 1.14 0.94 0.79 1.12 
      
 
Resilience 1.01 0.79 1.26 0.97 0.78 1.17 1.04 0.83 1.29 
      
 
Person-centeredness 1.06 0.79 1.34 1.11 0.87 1.39 1.18 0.90 1.50 
      
 
Continuity of care 0.85 0.65 1.09 0.87 0.68 1.09 0.99 0.77 1.24 
      
 
Total costs 0.89 0.57 1.24 1.11 0.81 1.48 0.82 0.52 1.17 
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